Allied Academic Publication is an amalgamation of several esteemed academic and scientific associations known for promoting scientific temperament. Established in the year 1997, Andrew John Publishing Group is a specialized Medical publisher that operates in collaboration with the association and societies.This publishing house has been built on the base of esteemed academic and research institutions including The College of Audiologists and Speech Language Pathologists of Ontario(CASLPO), The Association for Public Safety Communications Officials of Canada (APCO), The Canadian Vascular Access Association (CVAA), The Canadian Society of Internal Medicine (CSIM), The Canadian Hard of Hearing Association (CHHA), Sonography Canada, Canadian Association of Pathologists (CAP-ACP) and The Canadian Association of Neurophysiologic Monitoring (CANM).
Allied Academies extends the warm welcome to 2nd International Congress on Industrial Biotechnology during July 23-24, 2018 at Vancouver, Canada with a theme “Future prospects for Biotechnology and Economic Growth”. Allied Academies through its Open Access Initiative is committed to making genuine and reliable contributions to the scientific community.
Industrial Biotechnology 2018 aims to bring together the Professors, Researchers, scientists, business giants, and technocrats to provide an international forum for the dissemination of original research results, new ideas and practical development and discover advances in the field of biotechnology, management and education in relation to biotechnology as well as a breadth of other topics. The applications of biotechnology include therapeutics, diagnostics, and genetically modified crops for agriculture, processed food, bioremediation, waste treatment, and energy production. It is an excellent opportunity for the delegates from Universities and Institutes to interact with the world class Scientists.
Who can attend?
Industrial Biotech 2018 congress brings together individuals who have an interest in different fields of Biotechnology. Target Audience will be personnel from both industrial and academic fields which include; Professors, Researchers, scientists, business giants,CEOs, COOs, Directors, Vice Presidents, Co-directors, Biotechnologists, Managing Directors, Industry Safety Officers, Environmental & Plant Scientists, Doctorates, Professors, Post Doctorate Fellows, Vendors of Consumer Products/ Managers, Pharmaceutical Scientists, Students from the related fields.
Why to Attend???
Industrial Biotech 2018 provides a global platform for exchanging ideas and makes us updated about the latest innovations in healthcare. Opportunity to attend the presentations delivered by Eminent Scientists from all over the world.
Since the discovery of DNA in 1953, and the identification of DNA as the genetic material in all life, there have been tremendous advances in the vast area of biotechnology. Biotech has a wide range of uses including food alterations, genetic research and cloning, human and animal health care, pharmaceuticals and the environment. The Global Biotechnology industry comprises a diverse range of companies engaged in the development of pharmaceuticals, pest-resistant crops and biofuels, among other products. Revenue for the industry has grown over the past five years and global investment in biotechnology has increased consistently, with much of the added R&D spending funneled into medical applications aimed at providing care for the aging global population. The Global Biotechnology industry is in the growth phase of its economic life cycle. Over the 10 years to 2021, revenue and industry value added (IVA) growth have outpaced world GDP growth. IVA, which measures the industry's contribution to the overall global economy, is forecast to grow 3.5% per year on average during the 10 years to 2021, slightly greater than annualized global GDP growth of 2.7% over the same period. The rapid increase in demand reflects the significant expansion in the products the industry supplies. Product lines increase as new technology is developed, processes are learned and products commercialized.
Total Revenue in Biotechnology and Annual growth:
The global biotechnology market size was valued at USD 270.5 billion in 2013 and is expected to grow at a CAGR of 12.3% owing to the increasing demand for diagnostics and therapeutics solutions such as recombinant technology, red biotechnology, and DNA sequencing. The increasing prevalence of diseases such as cancer, hepatitis B, and other orphan disorders is expected to serve as a high-impact rendering driver for this industry over the forecast period. Rising government initiatives owing to high significance towards growth of the economy are expected to boost the biotechnology market growth over the forecast period.
Increasing demand for agricultural and food products such as wheat, rice, sugarcane, and beans owing to growing population base in countries such as the U.S., China, and India is another major factor positively impacting the growth of the industry. Factors such as limited availability of agricultural land, shortage of water, the low yield of crops, and pest attacks are encouraging researchers to develop innovative agricultural technologies via extensive R&D activities. Application of biotechnological processes such as Genetic Modification (GM) and genetic engineering on agricultural products is a major driver for the growth of this industry.
Key technologies include fermentation, tissue engineering, nanobiotechnology, PCR technology, DNA sequencing, chromatography, cell-based assay, and others. In 2013, the tissue engineering and regeneration segment dominated the overall industry with USD 87.92 billion revenue. However, the DNA sequencing and cell-based assay segment is expected to witness lucrative growth till 2020 due to rising research and development initiatives by various pharmaceutical and biotechnological companies.
DNA sequencing is expected to grow at a CAGR of over 18.1% owing to its wide applications in various verticals such as agriculture, biology, medical, and geology. Based on application, global biotechnology market is divided into biopharmaceutical, bioservices, bioagriculture, and bio industrial. In 2013, biopharmaceuticals that are segmented into advanced drugs, orphan drugs, monoclonal antibodies, and recombinant proteins dominated the overall industry with around USD 184.21 billion revenue. Asia Pacific is expected to gain substantial market share and reach around USD 145.9 billion by 2020. Escalating awareness about the advantages associated with adoption and introduction of healthcare benefits by the government are driving forces for this region. The market was dominated by Roche Diagnostics with a market share of 17.1% in 2013. Key strategies adopted by these companies to gain market share include strategic collaborations, mergers, outsourcing research & development, and manufacturing activities.